Correlation Between Sonoma Pharmaceuticals and Cannara Biotech

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sonoma Pharmaceuticals and Cannara Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sonoma Pharmaceuticals and Cannara Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sonoma Pharmaceuticals and Cannara Biotech, you can compare the effects of market volatilities on Sonoma Pharmaceuticals and Cannara Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sonoma Pharmaceuticals with a short position of Cannara Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sonoma Pharmaceuticals and Cannara Biotech.

Diversification Opportunities for Sonoma Pharmaceuticals and Cannara Biotech

0.21
  Correlation Coefficient

Modest diversification

The 3 months correlation between Sonoma and Cannara is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Sonoma Pharmaceuticals and Cannara Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cannara Biotech and Sonoma Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sonoma Pharmaceuticals are associated (or correlated) with Cannara Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cannara Biotech has no effect on the direction of Sonoma Pharmaceuticals i.e., Sonoma Pharmaceuticals and Cannara Biotech go up and down completely randomly.

Pair Corralation between Sonoma Pharmaceuticals and Cannara Biotech

Given the investment horizon of 90 days Sonoma Pharmaceuticals is expected to generate 1.13 times more return on investment than Cannara Biotech. However, Sonoma Pharmaceuticals is 1.13 times more volatile than Cannara Biotech. It trades about 0.06 of its potential returns per unit of risk. Cannara Biotech is currently generating about 0.0 per unit of risk. If you would invest  268.00  in Sonoma Pharmaceuticals on September 1, 2024 and sell it today you would earn a total of  11.00  from holding Sonoma Pharmaceuticals or generate 4.1% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Sonoma Pharmaceuticals  vs.  Cannara Biotech

 Performance 
       Timeline  
Sonoma Pharmaceuticals 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Sonoma Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, Sonoma Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point.
Cannara Biotech 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Cannara Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical and fundamental indicators, Cannara Biotech is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders.

Sonoma Pharmaceuticals and Cannara Biotech Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sonoma Pharmaceuticals and Cannara Biotech

The main advantage of trading using opposite Sonoma Pharmaceuticals and Cannara Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sonoma Pharmaceuticals position performs unexpectedly, Cannara Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cannara Biotech will offset losses from the drop in Cannara Biotech's long position.
The idea behind Sonoma Pharmaceuticals and Cannara Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device